| Drug Name |
Darifenacin hydrobromide |
| Drug ID |
BADD_D00585 |
| Description |
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention.
It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. |
| Indications and Usage |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. |
| Marketing Status |
approved; investigational |
| ATC Code |
G04BD10 |
| DrugBank ID |
DB00496
|
| KEGG ID |
D01699
|
| MeSH ID |
C101207
|
| PubChem ID |
444030
|
| TTD Drug ID |
D0Y5AM
|
| NDC Product Code |
53104-7706; 65862-881; 66039-861; 52605-067; 63415-0529; 70700-182; 69097-431; 71205-900; 71205-901; 48087-0110; 65372-1168; 50370-0007; 70700-183; 52605-068; 69097-432 |
| UNII |
CR02EYQ8GV
|
| Synonyms |
darifenacin | darifenacine | darifenicin | (S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide | darifenacin hydrochloride | Enablex | UK-88525 | darifenacin hydrobromide | Emselex |
